British Muslim teacher escorted off US flight hopes it was a mistake

February 24, 2017

Feb 24: A British Muslim teacher planned to accompany his students on a school trip to the American city of New York, but little did he know that he would be denied entry to the United States.

BritishJuhel Miah, 25, a math teacher, was escorted off the flight by American officials, thinking he was singled out because of his religious affiliation.

Miah was born in Birmingham and brought up in Swansea, said that he felt humiliated due to the treatment by American officials.

Both Miah and Llangatwg community school, near Neath, south Wales, are calling for an urgent clarification from the American authorities.

“No one could give me an explanation,” Miah said. “The only thing I can put it down to, unfortunately – I hope I'm wrong – is because I'm a Muslim. That's all I can put it down to. I hope that's not true.

“I'm not an angry type of person,” he told the UK's Guardian newspaper. “I don't get easily worked up; otherwise, I wouldn't be a teacher. But I was definitely angry. It hit me the hardest was when I was being escorted off the plane. Everyone was looking at me.”

Being targeted in front of not only passengers, but also the school's children and fellow teachers made Miah uncomfortable.

“It made me feel so small as if I had done something wrong, as if I am a criminal,” he said. “Everyone must have been thinking that – even the kids from my school. I hope not but that's what was going through my head. I didn't know where to look.”

The math teacher, whose parents are of Bangladeshi origin, argued that what happened to him should not be encountered by anyone.

The Welsh first minister, Carwyn Jones, has written to Foreign Secretary Boris Johnson asking for “urgent clarification.” The US has not commented.

Miah was one of other five teachers who were accompanying a party of 39 children to New York via Iceland last week.

While the party was catching their plane on to the United States, the problems started to emerge at Keflavík International Airport near Reykjavik.

“I gave one of the American officials there my passport. My first name is Mohammed. It felt as if straight away she looked up and said: ‘You've been randomly selected for a security check.' ”

Miah followed the American officials' instructions and followed her to a room. “There were five or six other officials. Two of them checked me. They made me take my jacket off, my hoodie off, they opened my bag, and I took my shoes off. They made me stand on a stool. They rubbed me all the way down. They even pulled my trousers down to check my boxers. They rubbed their hands under my feet. They got a swab and wiped me all over. Eventually, they let me go through.”

Miah, who has a degree from Swansea University, could see out of the corner of his eye an American official coming toward him while he was helping the eight students he was in charge of to settle. “She asked: ‘Are you Mohammed Miah? You need to come with me.' ” Miah was taken to the front of the plane and escorted off. “'I've just received a phone call. You are not allowed to go to New York and you are not allowed to be on this plane,' the official told me.”

The teacher was not given any explanation as to why he was escorted, despite being a British citizen with a valid visa.

Vouchers for a taxi and a hotel were all that have been given to Miah that day in compensation to what happened to him. He was made to wait outside the American embassy in Reykjavik in the rain the next day upon his arrival. “The security guard stopped me, took my passport, came back 10 minutes later. He didn't want to know. He gave me a card with three numbers on. There was no answer from the first number and the others did not ring out.”

The school made necessary arrangements for Maih to fly back to the United Kingdom. “I was going through everything. I was thinking have I said something on social media but I'm very careful because I'm a teacher,” he thought to himself while waiting to return home.

Neither Miah nor his family has ever been to any of the seven Muslim-majority countries listed in Trump's travel ban — Iran, Iraq, Syria, Yemen, Somalia, Sudan and Libya.

“My brother flew to Florida last year. I still can't pinpoint why me,” Miah wondered.

“I hope this isn't true, I really don't want this to be true but it all started with the first American official I met and the moment she read Mohammed.

Despite the unpleasant incident, Miah still wants to go to America one day. “I just hope it boils down to human error and someone says sorry,” the teacher said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
Agencies
August 7,2020

Russia boasts that it's about to become the first country to approve a Covid-19 vaccine, with mass vaccinations planned as early as October using shots that are yet to complete clinical trials -- and scientists worldwide are sounding the alarm that the headlong rush could backfire.

Moscow sees a Sputnik-like propaganda victory, recalling the Soviet Union's launch of the world's first satellite in 1957.

But the experimental Covid-19 shots began first-in-human testing on a few dozen people less than two months ago, and there's no published scientific evidence yet backing Russia's late entry to the global vaccine race, much less explaining why it should be considered a front-runner.

“I'm worried that Russia is cutting corners so that the vaccine that will come out may be not just ineffective, but also unsafe,” said Lawrence Gostin, a global public health law expert at Georgetown University. “It doesn't work that way... Trials come first. That's really important.”

According to Kirill Dmitriev, head of Russia's Direct Investment Fund that bankrolled the effort, a vaccine developed by the Gamaleya research institute in Moscow may be approved in days, before scientists complete what's called a Phase 3 study.

That final-stage study, usually involving tens of thousands of people, is the only way to prove if an experimental vaccine is safe and really works.

Health Minister Mikhail Murashko said members of “risk groups,” such as medical workers, may be offered the vaccine this month.

He didn't clarify whether they would be part of the Phase 3 study that is said to be completed after the vaccine receives “conditional approval.”

Deputy Prime Minister Tatyana Golikova promised to start “industrial production” in September, and Murashko said mass vaccination may begin as early as October.

Dr Anthony Fauci, the top US infectious disease specialist, questioned the fast-track approach last week.

“I do hope that the Chinese and the Russians are actually testing a vaccine before they are administering the vaccine to anyone, because claims of having a vaccine ready to distribute before you do testing I think is problematic at best," he said.

Questions about this vaccine candidate come after the US, Britain and Canada last month accused Russia of using hackers to steal vaccine research from Western labs.

Delivering a vaccine first is a matter of national prestige for the Kremlin as it tries to assert the image of Russia as a global power capable of competing with the US and China.

The notion of being “the first in the world” dominated state news coverage of the effort, with government officials praising reports of the first-step testing.

In April, President Vladimir Putin ordered state officials to shorten the time of clinical trials for a variety of drugs, including potential coronavirus vaccines.

According to Russia's Association of Clinical Trials Organizations, the order set “an unattainable bar” for scientists who, as a result, "joined in on the mad race, hoping to please those at power.”

The association first raised concern in late May, when professor Alexander Gintsburg, head of the Gamaleya institute, said he and other researchers tried the vaccine on themselves.

The move was a “crude violation of the very foundations of clinical research, Russian law and universally accepted international regulations" the group said in an open letter to the government, urging scientists and health officials to adhere to clinical research standards.

But a month later, the Health Ministry authorized clinical trials of the Gamaleya product, with what appeared to be another ethical issue.

Human studies started June 17 among 76 volunteers. Half were injected with a vaccine in liquid form and the other half with a vaccine that came as soluble powder.

Some in the first half were recruited from the military, which raised concerns that servicemen may have been pressured to participate.

Some experts said their desire to perform well would affect the findings. “It's no coincidence media reports we see about the trials among the military said no one had any side effects, while the (other group) reported some," said Vasily Vlassov, a public health expert with Moscow's Higher School of Economics.

As the trials were declared completed and looming regulatory approval was announced last week, questions arose about the vaccine's safety and effectiveness.

Government assurances the drug produced the desired immune response and caused no significant side effects were hardly convincing without published scientific data describing the findings.

The World Health Organization said all vaccine candidates should go through full stages of testing before being rolled out.

“There are established practices and there are guidelines out,” WHO spokesman Christian Lindmeier said Tuesday.

“Between finding or having a clue of maybe having a vaccine that works, and having gone through all the stages, is a big difference.”

Offering an unsafe compound to medical workers on the front lines of the outbreak could make things worse, Georgetown's Gostin said, adding: “What if the vaccine started killing them or making them very ill?”

Vaccines that are not properly tested can cause harm in many ways — from a negative impact on health to creating a false sense of security or undermining trust in vaccinations, said Thomas Bollyky, director of the global health program at the Council on Foreign Relations. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
July 2,2020

Geneva, Jul 2: The World Health Organization (WHO) has estimated the overall number of coronavirus cases globally at 10,357,662, with 508,055 people having died from the disease.

The UN health agency said in the situation report published on late Wednesday that 163,939 new cases had been recorded in the past day, while further 4,188 patients had died.

Americas continue to lead the count with over 5.2 million cases, followed by Europe with more than 2.7 million.

The WHO declared the COVID-19 outbreak a pandemic on March 11.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
May 19,2020

May 19: A Chinese laboratory has been developing a drug it believes has the power to bring the coronavirus pandemic to a halt.

The outbreak first emerged in China late last year before spreading across the world, prompting an international race to find treatments and vaccines.

A drug being tested by scientists at China's prestigious Peking University could not only shorten the recovery time for those infected, but even offer short-term immunity from the virus, researchers say.

Sunney Xie, director of the university's Beijing Advanced Innovation Center for Genomics, told AFP that the drug has been successful at the animal testing stage.

"When we injected neutralising antibodies into infected mice, after five days the viral load was reduced by a factor of 2,500," said Xie.

"That means this potential drug has (a) therapeutic effect."

The drug uses neutralising antibodies -- produced by the human immune system to prevent the virus infecting cells -- which Xie's team isolated from the blood of 60 recovered patients.

A study on the team's research, published Sunday in the scientific journal Cell, suggests that using the antibodies provides a potential "cure" for the disease and shortens recovery time.

Xie said his team had been working "day and night" searching for the antibody.

"Our expertise is single-cell genomics rather than immunology or virology. When we realised that the single-cell genomic approach can effectively find the neutralising antibody we were thrilled."

He added that the drug should be ready for use later this year and in time for any potential winter outbreak of the virus, which has infected 4.8 million people around the world and killed more than 315,000.

"Planning for the clinical trial is underway," said Xie, adding it will be carried out in Australia and other countries since cases have dwindled in China, offering fewer human guinea pigs for testing.

"The hope is these neutralised antibodies can become a specialised drug that would stop the pandemic," he said.

China already has five potential coronavirus vaccines at the human trial stage, a health official said last week.

But the World Health Organization has warned that developing a vaccine could take 12 to 18 months.

Scientists have also pointed to the potential benefits of plasma -- a blood fluid -- from recovered individuals who have developed antibodies to the virus enabling the body's defences to attack it.

More than 700 patients have received plasma therapy in China, a process which authorities said showed "very good therapeutic effects".

"However, it (plasma) is limited in supply," Xie said, noting that the 14 neutralising antibodies used in their drug could be put into mass production quickly.

Using antibodies in drug treatments is not a new approach, and it has been successful in treating several other viruses such as HIV, Ebola and Middle East Respiratory Syndrome (MERS).

Xie said his researchers had "an early start" since the outbreak started in China before spreading to other countries.

Ebola drug Remdesivir was considered a hopeful early treatment for COVID-19 -- clinical trials in the US showed it shortened the recovery time in some patients by a third -- but the difference in mortality rate was not significant.

The new drug could even offer short-term protection against the virus.

The study showed that if the neutralising antibody was injected before the mice were infected with the virus, the mice stayed free of infection and no virus was detected.

This may offer temporary protection for medical workers for a few weeks, which Xie said they are hoping to "extend to a few months".

More than 100 vaccines for COVID-19 are in the works globally, but as the process of vaccine development is more demanding, Xie is hoping that the new drug could be a faster and more efficient way to stop the global march of the coronavirus.

"We would be able to stop the pandemic with an effective drug, even without a vaccine," he said.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.